Moore Capital Management, LP Affimed N.V. Transaction History

Moore Capital Management, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$1.44 - $3.02 $72,000 - $151,000	-50,000 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$2.25 - $3.07 $112,500 - $153,500	50,000 New	50,000 $137,000
Q1 2018 May 15, 2018	SELL	$1.25 - $2.65 $156,250 - $331,250	-125,000 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$1.23 - $2.3 $153,750 - $287,500	-125,000 Reduced 50.0%	125,000 $163,000
Q3 2017 Nov 14, 2017	BUY	$1.95 - $2.25 $487,500 - $562,500	250,000	250,000 $563,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $391M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Moore Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Moore Capital Management, LP with notifications on news.